ADHERENCE AND PERSISTENCE WITH DULOXETINE VERSUS ESCITALOPRAM AMONG HIGH HEALTHCARE RESOURCES UTILIZERS WITH MAJOR DEPRESSIVE DISORDER

Author(s)

Tepper P1, Liu X2, Able SL2, Johnstone B21University of Pittsburgh, Pittsburgh, PA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

OBJECTIVES: Adherence and persistence to prescribed medication is important in the management of major depressive disorder (MDD). This study compared adherence and persistence between duloxetine and escitalopram among high health care utilizers with MDD. METHODS: In a large US commercial managed-care claims database, 10,803 MDD patients (18 to 64 years) who initiated on duloxetine (n=4,542) or escitalopram (n=6,261) during the calendar year 2006 were identified. All of the patients had no recorded prescription of study medications for 6 months prior to initiation and had continuous enrollment for 12 months prior to and post-medication initiation. High health care utilizers (duloxetine, n=3,113; escitalopram, n=3,157) were defined as patients whose total treatment costs in the prior 1 year were above the median of total costs for all MDD patients in 2005. Adherence was defined as Medication Possession Ratio (MPR) ≥0.8, and persistence was defined as the length of therapy without exceeding a 30-day gap. Statistical analyses included chi-square test, Wilcoxon rank sum test, multivariate logistic and Cox regression. RESULTS: In the post 6 months (6M) and 12 months (12M), adherence rates were significantly higher for duloxetine-treated patients (6M 54.6% and 12M 40.9%) than escitalopram-treated patients (6M 47.4% and 12M 31.7%) (p values <.001). Duloxetine-treated patients also stayed on the medication significantly longer (6M 115.9 days and 12M 171.1 days) than escitalopram-treated patients (6M 108.4 days and 12M 154.6 days) (p values <.001). Results were essentially unchanged with adjustment for demographics, comorbid conditions, prior medications use, and healthcare utilization, resulting in duloxetine therapy maintaining its better adherence and longer persistence versus escitalopram. CONCLUSIONS: Duloxetine-treated patients appear to be more adherent and have a longer stay on the medication than escitalopram-treated patients for high resources utilizers. Further research is needed to examine clinical and economic benefits of better adherence and persistence with duloxetine therapy.

Conference/Value in Health Info

2010-09, ISPOR Asia Pacific 2010, Phuket, Thailand

Value in Health, Vol. 13, No. 7 (November 2010)

Code

PMH14

Topic

Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance

Disease

Mental Health

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×